HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4580 Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL). Jan 17 2024
E1769 Merbarone Merbarone(NSC 336628) is a catalytic inhibitor of topoisomerase II with IC50 of 120 μM, with anti-proliferative activity against human cancer cells. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Jan 17 2024
E1604 Vevorisertib trihydrochloride Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) is a selective, allosteric inhibitor of pan-AKT and AKT1-E17K mutant with Kd values of 1.2 nM and 8.6 nM, respectively. It also has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively and can be used for the research of cancer. Jan 16 2024
A3176 Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Jan 15 2024
E1667 LY2880070 LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents. Jan 10 2024
E1812 N6F11 N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. Jan 10 2024
E1739 MST-312 MST-312(Telomerase Inhibitor IX) is an inhibitor of telomerase. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 exhibits high chemical stability, lowers the effective dose in the induction of telomere shortening, and lowers drug resistance. MST-312 can be used for the research of cancer. MST-312 can also be used as a promising strategy in the treatment of multiple myeloma (MM). Jan 10 2024
E1658 PRT543 PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. Jan 09 2024
E1744 UNC5293 UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM. Jan 09 2024
E1742 Reversan Reversan (CBLC4H10) is a selective and nontoxic inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp), with the potential to treat neuroblastoma and other MRP1-overexpressing drug-refractory tumors. Jan 09 2024
E1723 NSC16168 NSC16168 is a specific inhibitor of ERCC1-XPF, and exhibits an IC50 value of 0.42 μM in a high throughput screen (HTS) assay, respectively. NSC16168 inhibits DNA repair and potentiates cisplatin efficacy in cancer. Jan 09 2024
E1746 Protokylol hydrochloride Protokylol hydrochloride(Caytine hydrochloride, JB-251 hydrochloride) is a salt form of protokylol and is an agonist of β-adrenergic receptor. Protokylol hydrochloride is also used as a bronchodilator. Jan 07 2024
E1727 Pimicotinib Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities. Jan 07 2024
E1564 BI-2493 BI-2493, a structural analogue of BI-2865, is a highly selective inhibitor of pan-KRAS. BI-2493 attenuates tumor growth and can be used for cancer research. Jan 07 2024
E1620 Fluorofurimazine Fluorofurimazine is a novel furimazine analogue, with increased aqueous solubility enabling higher signal emission than furimazine for bioluminescence imaging. Fluorofurimazine enables higher substrate loading and improved optical imaging sensitivity in in-vivo. Jan 04 2024
A3175 Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. Jan 03 2024
E1435 Tinengotinib Tinengotinib (TT-00420) is a novel multiple kinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM respectively. It also exhibits potent inhibitory activity on FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat several prominent signaling pathways in triple-negative breast cancer(TNBC). Jan 01 2024
E1649 Exarafenib Exarafenib(KIN-002787, KIN-2787, RAF/KIN_2787) is an orally-available, selective inhibitor of pan-RAF. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. KIN-2787 exhibits low nanomolar to picomolar potency against RAF1, BRAF, and ARAF with an IC50 of 0.06-3.46 nM with minimal activity towards non-RAF kinases. Dec 28 2023
E1708 Solutol HS-15 Solutol HS-15(Polyethylene glycol 12-hydroxystearate) is a Macrogol 15 hydroxy stearate, which improves permeability by disrupting the membrane structure/fluidity change. Dec 27 2023
S9463 Demecarium Bromide Demecarium Bromide, an anticholinesterase, is an inhibitor of monoamine oxidase (MAO). It induces long-term miosis and decreases intraocular pressure (IOP) in normotensive eyes of Beagles and of eyes of Beagles with inherited glaucoma. Dec 26 2023